RMHI · CIK 0001452804
PEAK PHARMACEUTICALS, INC.
Annual figures as reported, FY2011–FY2022. Ratios and growth rates derived on-page.
Pharmaceutical Preparations
Company profile
Net income
−$165K
▼ −116.8% vs FY2021
Operating cash flow
−$69K
▼ −380.9% vs FY2021
Diluted EPS
$0.00
Net income
Losses shown in terracotta
Recent quarters
momentum · last 12 quartersNet income — Dec ’22 quarter
−$112K
▼ −89.1% vs Dec ’21
Diluted EPS — trailing 12 months
$0.00
Quarterly net income
Losses shown in terracotta
| Quarter | Revenue | Rev. YoY | Gross margin | Net income | Net margin | Diluted EPS |
|---|---|---|---|---|---|---|
| Dec ’22 | — | — | — | −$112K | — | — |
| Sep ’22 | — | — | — | −$60K | — | — |
| Jun ’22 | — | — | — | $9K | — | $0.00 |
| Mar ’22 | — | — | — | −$55K | — | $0.00 |
| Dec ’21 | — | — | — | −$59K | — | $0.00 |
| Sep ’21 | — | — | — | −$7K | — | $0.00 |
| Jun ’21 | — | — | — | −$19K | — | $0.00 |
| Mar ’21 | — | — | — | −$43K | — | $0.00 |
Profitability & returns
quality of earningsReturns on capital
Net income vs year-end equity and assets
Return on equityReturn on assets
Cash flow
cash generationOperating cash flow
Net cash from operations
Balance sheet
financial positionStockholders’ equity
At fiscal year end
Key ratios
derived per fiscal year| Fiscal year | ROE | ROA | Current ratio |
|---|---|---|---|
| FY2022 | — | −126.6% | — |
| FY2021 | — | −29.1% | — |
| FY2020 | — | −3679.2% | 0.00× |
| FY2019 | — | −2655.2% | 0.00× |
| FY2018 | — | −1251.4% | 0.01× |
| FY2017 | — | −1712.7% | 0.02× |
| FY2016 | 821.6% | 89128.5% | 0.01× |
| FY2015 | — | −820.3% | 0.90× |
| FY2014 | −861.2% | −765.7% | 8.42× |
| FY2013 | — | −251.5% | 0.11× |
| FY2012 | −75.2% | −245.7% | 0.23× |
| FY2011 | — | −204.9% | — |
Annual figures
as reported| Fiscal year | Revenue | Gross profit | Op. income | Net income | Diluted EPS | Op. cash flow | Capex | Total assets | Liabilities | Equity | Cash | LT debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2022 | — | — | −$163K | −$165K | — | −$69K | — | $130K | $622K | −$491K | — | — |
| FY2021 | — | — | −$69K | −$76K | $0.00 | −$14K | — | $261K | $587K | −$326K | — | — |
| FY2020 | — | — | −$6K | −$15K | $0.00 | −$119 | — | $408 | $251K | −$250K | $0 | — |
| FY2019 | — | — | −$6K | −$14K | $0.00 | −$2K | — | $527 | $236K | −$235K | $0 | — |
| FY2018 | — | — | −$28K | −$28K | $0.00 | −$44K | — | $2K | $223K | −$221K | $0 | — |
| FY2017 | — | — | −$45K | −$51K | $0.00 | −$18K | — | $3K | $196K | −$193K | $0 | — |
| FY2016 | — | — | $1.1M | $1.2M | — | −$200K | — | $1K | $143K | $141K | — | — |
| FY2015 | — | — | −$2.3M | −$2.3M | — | −$248K | — | $281K | $289K | −$7K | — | — |
| FY2014 | — | — | — | −$3.8M | — | −$933K | — | $491K | $54K | $436K | $451K | — |
| FY2013 | — | — | — | −$12K | $0.00 | −$16K | — | $5K | $44K | −$39K | $5K | — |
| FY2012 | — | — | — | −$20K | $0.00 | −$19K | — | $8K | $35K | $27K | $5K | — |
| FY2011 | — | — | — | −$16K | $0.00 | −$13K | — | $8K | $14K | −$7K | $5K | — |
Latest filings
the most recent regulatory filingsDSEC filing2024-10-28 ↗C-USEC filing2024-09-17 ↗C/ASEC filing2024-05-10 ↗CSEC filing2024-03-14 ↗DSEC filing2023-08-14 ↗15-12GPEAK PHARMACEUTICALS, INC. FORM 15-12G2023-03-21 ↗10-QPEAK PHARMACEUTICALS 12/31/22 FORM 10-Q2023-02-09 ↗8-KPEAK PHARMACEUTICALS, INC. 8-K2023-01-20 ↗10-KPEAK PHARMACEUTICALS, INC. 09/30/2022 10-K2022-12-19 ↗10-QPEAK PHARMACEUTICALS, INC. 06/30/2022 10-Q2022-12-19 ↗
Company logos by Elbstream and unavatar.
All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.